US 12,077,587 B2
Anti-CD8 antibodies and uses thereof
Jason T. Giurleo, Franklin Lakes, NJ (US); Dangshe Ma, Millwood, NY (US); William Olson, Yorktown Heights, NY (US); Gavin Thurston, Briarcliff Manor, NY (US); and Richard Tavare, Croton-on-Hudson, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 26, 2022, as Appl. No. 18/049,972.
Application 18/049,972 is a continuation of application No. 16/914,112, filed on Jun. 26, 2020, granted, now 11,525,001.
Application 16/914,112 is a continuation of application No. 16/043,048, filed on Jul. 23, 2018, granted, now 10,730,944, issued on Aug. 4, 2020.
Claims priority of provisional application 62/660,902, filed on Apr. 20, 2018.
Claims priority of provisional application 62/536,239, filed on Jul. 24, 2017.
Prior Publication US 2023/0159639 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); A61K 51/10 (2006.01); G01N 33/53 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2815 (2013.01) [A61K 45/06 (2013.01); A61K 49/0032 (2013.01); A61K 49/0058 (2013.01); A61K 51/1027 (2013.01); C07K 16/2818 (2013.01); G01N 33/53 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A composition comprising:
(i) a radiolabeled antibody conjugate comprising an antibody or antigen binding fragment thereof that binds CD8, a chelating moiety, and a positron emitter, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 2; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 10; and
(ii) CD8 expressing T cells.